Literature DB >> 24590257

Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

Florian Seemüller1, Sebastian Meier, Michael Obermeier, Richard Musil, Michael Bauer, Mazda Adli, Klaus Kronmüller, Florian Holsboer, Peter Brieger, Gerd Laux, Wolfram Bender, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Michael Riedel, Peter Falkai, Hans-Jürgen Möller.   

Abstract

In randomized controlled trials, maintenance treatment for relapse prevention has been proven to be efficacious in patients responding in acute treatment, its efficacy in long-term outcome in "real-world patients" has yet to be proven. Three-year long-term data from a large naturalistic multisite follow-up were presented. Severe relapse was defined as suicide, severe suicide attempt, or rehospitalization. Next to relapse rates, possible risk factors including antidepressant medication were identified using univariate generalized log-rank tests and multivariate Cox proportional hazards model for time to severe relapse. Overall data of 458 patients were available for analysis. Of all patients, 155 (33.6%) experienced at least one severe relapse during the 3-year follow-up. The following variables were associated with a shorter time to a severe relapse in univariate and multivariate analyses: multiple hospitalizations, presence of avoidant personality disorder, continuing antipsychotic medication, and no further antidepressant treatment. In comparison with other studies, the observed rate of severe relapse during 3-year period is rather low. This is one of the first reports demonstrating a beneficial effect of long-term antidepressant medication on severe relapse rates in naturalistic patients. Concomitant antipsychotic medication may be a proxy marker for treatment resistant and psychotic depression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590257     DOI: 10.1007/s00406-014-0495-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  30 in total

1.  Why do you need to move beyond first-line therapy for major depression?

Authors:  Larry Culpepper
Journal:  J Clin Psychiatry       Date:  2010       Impact factor: 4.384

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Factors associated with readmission to a psychiatric facility.

Authors:  A C Bernardo; C Forchuk
Journal:  Psychiatr Serv       Date:  2001-08       Impact factor: 3.084

4.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

5.  Tachyphylaxis in unipolar major depressive disorder.

Authors:  David A Solomon; Andrew C Leon; Timothy I Mueller; William Coryell; Jedediah J Teres; Michael A Posternak; Lewis L Judd; Jean Endicott; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

6.  Factors affecting time to rehospitalization for patients with major depressive disorder.

Authors:  Ching-Hua Lin; Yong-Shing Chen; Chieh-Hsin Lin; Keng-Shin Lin
Journal:  Psychiatry Clin Neurosci       Date:  2007-06       Impact factor: 5.188

7.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

Authors:  E Frank; R F Prien; R B Jarrett; M B Keller; D J Kupfer; P W Lavori; A J Rush; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1991-09

Review 8.  Recurrence in major depressive disorder: a neurocognitive perspective.

Authors:  O J Robinson; B J Sahakian
Journal:  Psychol Med       Date:  2008-03       Impact factor: 7.723

9.  Psychotic and neurotic depression: discriminant function analysis and five-year outcome.

Authors:  J R Copeland
Journal:  Psychol Med       Date:  1983-05       Impact factor: 7.723

10.  Outcomes of 1014 naturalistically treated inpatients with major depressive episode.

Authors:  Florian Seemüller; Michael Riedel; Michael Obermeier; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Eva Dichgans; Roland Bottländer; Richard Musil; Hans-Jürgen Möller
Journal:  Eur Neuropsychopharmacol       Date:  2010-01-22       Impact factor: 4.600

View more
  16 in total

1.  Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10       Impact factor: 5.270

2.  Clinical and genetic factors associated with suicide in mood disorder patients.

Authors:  Niki Antypa; Daniel Souery; Mario Tomasini; Diego Albani; Federica Fusco; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-12-01       Impact factor: 5.270

3.  Longterm persistence and nonrecurrence of depression treatment in Germany: a four-year retrospective follow-up using linked claims data.

Authors:  Christoph J Wagner; Charalabos Markos Dintsios; Florian G Metzger; Helmut L'Hoest; Ursula Marschall; Bjoern Stollenwerk; Stephanie Stock
Journal:  Int J Methods Psychiatr Res       Date:  2018-02-15       Impact factor: 4.035

Review 4.  Suicide Rates After Discharge From Psychiatric Facilities: A Systematic Review and Meta-analysis.

Authors:  Daniel Thomas Chung; Christopher James Ryan; Dusan Hadzi-Pavlovic; Swaran Preet Singh; Clive Stanton; Matthew Michael Large
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

5.  Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health.

Authors:  Allison C Nugent; Nicolas D Iadarola; Frank G Miller; David A Luckenbaugh; Carlos A Zarate
Journal:  Lancet Psychiatry       Date:  2016-03-10       Impact factor: 27.083

Review 6.  Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.

Authors:  Rafael T de Sousa; Marcus V Zanetti; Andre R Brunoni; Rodrigo Machado-Vieira
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

7.  The impact of residual symptoms on relapse and quality of life among Thai depressive patients.

Authors:  Thanita Hiranyatheb; Daochompu Nakawiro; Tinakon Wongpakaran; Nahathai Wongpakaran; Putipong Bookkamana; Manee Pinyopornpanish; Nattha Saisavoey; Kamonporn Wannarit; Sirina Satthapisit; Sitthinant Tanchakvaranont
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-12       Impact factor: 2.570

8.  Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients.

Authors:  Florian Seemüller; Michael Obermeier; Rebecca Schennach; Michael Bauer; Mazda Adli; Peter Brieger; Gerd Laux; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  BMC Psychiatry       Date:  2016-05-20       Impact factor: 3.630

9.  Cognitive and affective trait and state factors influencing the long-term symptom course in remitted depressed patients.

Authors:  Christina Timm; Bettina Ubl; Vera Zamoscik; Ulrich Ebner-Priemer; Iris Reinhard; Silke Huffziger; Peter Kirsch; Christine Kuehner
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

10.  Eye-Tracking Based Attention Bias Modification (ET-ABM) Facilitates Disengagement from Negative Stimuli in Dysphoric Individuals.

Authors:  Martin Möbius; Gina R A Ferrari; Robin van den Bergh; Eni S Becker; Mike Rinck
Journal:  Cognit Ther Res       Date:  2018-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.